Diabetic Ketoacidosis and Profound Insulin Resistance From Brentuximab Vedotin-Reference-Cited by-同舟云学术

Diabetic Ketoacidosis and Profound Insulin Resistance From Brentuximab Vedotin

Published:2023-03-05 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Thakkar Keval,Khurana Sonali,Sun Yujiao,Hembree Timothy N

Publisher

Springer Science and Business Media LLC

Subject

Aerospace Engineering

Reference10 articles.

1. Brentuximab vedotin;van de Donk NW;MAbs,2012

2. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review;Donato EM;Onco Targets Ther,2018

3. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma;Vaklavas C;Ther Adv Hematol,2012

4. Brentuximab vedotin-associated diabetic ketoacidosis: a case report;Köksalan D;Int J Diabetes Dev Ctries,2022

5. FDA Adverse Event Reporting System (FAERS) Public Dashboard. (2020). Accessed. February 5, 2020: https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/a....

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Refractory insulin resistance and hemophagocytic lymphohistiocytosis following enfortumab vedotin treatment: A case report;Molecular and Clinical Oncology;2024-05-08

2. Severe insulin resistance in a patient with diabetes after treatment with brentuximab vedotin;BMJ Case Reports;2024-04

3. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-01-25

4. Severe Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis (HLH)-Like Syndrome Following Administration of Combined Brentuximab Vedotin and Nivolumab for Recurrent Classical Hodgkin Lymphoma: A Case Report;Journal of Blood Medicine;2024-01